{"id":"hcp1904-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inducing proteasomal degradation of the androgen receptor rather than simply blocking its activity, HCP1904-1 eliminates both the full-length receptor and constitutively active truncated variants that can drive treatment-resistant disease. This mechanism is designed to overcome resistance mechanisms seen with traditional androgen receptor antagonists in hormone-sensitive and castration-resistant prostate cancer.","oneSentence":"HCP1904-1 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:59.312Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Castration-resistant prostate cancer (CRPC)"},{"name":"Hormone-sensitive prostate cancer"}]},"trialDetails":[{"nctId":"NCT05407220","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2022-06-29","conditions":"Healthy","enrollment":16},{"nctId":"NCT05723549","phase":"PHASE1","title":"A Study to Evaluate the PK, Safety and Tolerability of HCP1803.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2023-02-02","conditions":"Healthy","enrollment":20},{"nctId":"NCT04820907","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2020-10-27","conditions":"Hypertension","enrollment":123},{"nctId":"NCT05191563","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2021-07-31","conditions":"Healthy","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HCP1904-1","genericName":"HCP1904-1","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HCP1904-1 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC), Hormone-sensitive prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}